Eli Lilly to Issue Up to 40-Year Bonds to Fund $2.5 Billion Acquisition of Scorpion Therapeutics

Gelonghui February 11 | Eli Lilly and Company plans to issue bonds in the U.S. investment-grade bond market to finance its acquisition of Scorpion Therapeutics, Inc. and its cancer drugs for approximately $2.5 billion. According to informed sources, the longest tenor of the bonds issued by Eli Lilly will be 40-year Treasury bonds, with a coupon rate potentially 1.15 basis points higher than U.S. Treasury bonds.